|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Multifocal Neuropathy Evaluation
Test Code92823
CPT Codes
81324, 83520 (x4)<br>Limited Access Code
Physician Attestation of Informed Consent
This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA.
Includes
Co-GM1 Quattro™, PMP22 Duplication/Deletion Test
Preferred Specimen
2 mL serum, and
8 mL whole blood in two EDTA (lavender-top) tubes
8 mL whole blood in two EDTA (lavender-top) tubes
Minimum Volume
0.5 mL serum • 6 mL whole blood
Instructions
Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Serum must be separated from cells within 48 hours of collection.
Serum must be separated from cells within 48 hours of collection.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 10 days
Refrigerated: 10 days
Frozen: Unacceptable
Refrigerated: 10 days
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis; Icteric; Lipemia
Methodology
Enzyme-Linked Immunosorbent Assay (ELISA) • Multiplex Ligation-dependent Probe Amplification
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Tuesday Morning
Report available: 14 Days
Report available: 14 Days
Reference Range
See Laboratory Report
Clinical Significance
Anti-GM1, anti-GD1a, anti-Asialo GM1, anti-GD1b
antibodies, and PMP22 gene deletions are found in
patients with slowly progressive, predominantly distal,
asymmetric weakness with no sensory symptoms or signs.
Weakness is sometimes present in one upper extremity in
80% of patients; muscle atrophy is common.
antibodies, and PMP22 gene deletions are found in
patients with slowly progressive, predominantly distal,
asymmetric weakness with no sensory symptoms or signs.
Weakness is sometimes present in one upper extremity in
80% of patients; muscle atrophy is common.